Recognizing the need for personalization of haemophilia patient-reported outcomes in the prophylaxis era

Haemophilia

Volumn 22, Issue 6, 2016, Pages 825-832

  Recht, M ^a   Konkle, B A ^b   Jackson, S ^c   Neufeld, E J ^d   Rockwood, K ^e   Pipe, S ^f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e DALHOUSIE UNIVERSITY   (Canada)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

function; haemophilia; outcomes; patient reported outcomes; personalized medicine; quality of life

Indexed keywords

BLEEDING; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FUNCTIONAL ASSESSMENT; GENERAL HEALTH STATUS ASSESSMENT; GOAL ATTAINMENT; GOAL ATTAINMENT SCALING; HEMOPHILIA; HUMAN; MEDICAL INFORMATION SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT-REPORTED OUTCOME; PERSONALIZED MEDICINE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REVIEW; X RAY; HEMOPHILIA A; TREATMENT OUTCOME;

HEMOPHILIA A; HUMANS; PRECISION MEDICINE; TREATMENT OUTCOME;

EID: 84992208964     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13066     Document Type: Review

References (56)

1. Ljung R, Gretenkort Andersson N. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol 2015; 169: 777–86.
2. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44.
3. Pocoski J, Benjamin K, Michaels LA et al. An overview of current trends and gaps in patient-reported outcome measures used in haemophilia. Eur J Haematol 2014; 93(Suppl 75): 1–8.
4. Khair K. Compliance, concordance and adherence: What are we talking about? Haemophilia 2014; 20: 601–3.
5. Lock J, Raat H, Duncan N et al. Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale. Haemophilia 2014; 20: 616–23.
6. Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004; 63: 723–9.
7. Anderson DA, Christison-Lagay J, Proctor-Grey E. Self-management goal setting in a community health center: the impact of goal attainment on diabetes outcomes. Diabetes Spectr 2010; 23: 97–105.
8. Golan D, Staun-Ram E, Miller A. Shifting paradigms in multiple sclerosis: from disease-specific, through population-specific toward patient-specific. Curr Opin Neurol 2016; 29: 354–61.
9. Weller K, Zuberbier T, Maurer M. Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. Curr Opin Allergy Clin Immunol 2015; 15: 220–6.
10. Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med 2015; 372: 2229–34.
11. Blanchette VS, O'Mahony B, McJames L et al. Assessment of outcomes. Haemophilia 2014; 20(Suppl 4): 114–20.
12. Poonnoose P, Keshava S, Gibikote S et al. Outcome assessment and limitations. Haemophilia 2012; 18(Suppl 4): 125–30.
13. van den Berg HM, Feldman BM, Fischer K et al. Assessments of outcome in haemophilia – What is the added value of QoL tools? Haemophilia 2015; 21: 430–5.
14. Boehlen F, Graf L, Berntorp E. Outcome measures in haemophilia: a systematic review. Eur J Haematol 2014; 93: 2–15.
15. Fischer K, van Hout BA, van der Bom JG et al. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002; 43: 528–32.
16. Kidder W, Nguyen S, Larios J et al. Point-of-care musculoskeletal ultrasound is critical for the diagnosis of hemarthroses, inflammation and soft tissue abnormalities in adult patients with painful haemophilic arthropathy. Haemophilia 2015; 21: 530–7.
17. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745–52.
18. Iorio A, Marchesini E, Marcucci M et al. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011: CD003429.
19. Stephensen D, Drechsler WI, Scott OM. Outcome measures monitoring physical function in children with haemophilia: a systematic review. Haemophilia 2014; 20: 306–21.
20. Bladen M, Main E, Hubert N et al. Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia. Haemophilia 2013; 19: 626–31.
21. Saulyte Trakymiene S, Ingerslev J, Rageliene L. Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania. Haemophilia 2010; 16: 479–86.
22. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59: 287–305.
23. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153–9.
24. Lundin B, Manco-Johnson ML, Ignas DM et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012; 18: 962–70.
25. Lundin B, Hong W, Raunig D et al. 3-year analyses from SPINART: patient- and joint-level changes in magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia 2015; 21(Suppl 2): 40–1.
26. Altisent C, Martorell M, Crespo A et al. Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes. Haemophilia 2016; 22: 218–224.
27. Aledort L, Bullinger M, von Mackensen S et al. Why should we care about quality of life in persons with haemophilia? Haemophilia 2012; 18: e154–7.
28. Riva S, Bullinger M, Amann E et al. Content comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY). Health Qual Life Outcomes 2010; 8: 139.
29. World Health Organization. International Classification of Functioning, Disability, and Health: Children & Youth Version: ICF-CY. Geneva, Switzerland: World Health Organization, 2007.
30. Rentz A, Flood E, Altisent C et al. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia. Haemophilia 2008; 14: 1023–34.
31. Remor E, Arranz P, Quintana M et al. Psychometric field study of the new haemophilia quality of life questionnaire for adults: the ‘Hemofilia-QoL’. Haemophilia 2005; 11: 603–10.
32. Bullinger M, von Mackensen S, Fischer K et al. Pilot testing of the ‘Haemo-QoL’ quality of life questionnaire for haemophiliac children in six European countries. Haemophilia 2002; 8(Suppl 2): 47–54.
33. von Mackensen S, Bullinger M. Development and testing of an instrument to assess the quality of life of children with haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10(Suppl 1): 17–25.
34. von Mackensen S, Campos IG, Acquadro C et al. Cross-cultural adaptation and linguistic validation of age-group-specific haemophilia patient-reported outcome (PRO) instruments for patients and parents. Haemophilia 2013; 19: e73–83.
35. Young NL, Bradley CS, Blanchette V et al. Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT). Haemophilia 2004; 10(Suppl 1): 34–43.
36. McCusker PJ, Fischer K, Holzhauer S et al. International cross-cultural validation study of the Canadian Haemophilia Outcomes: Kids’ Life Assessment Tool. Haemophilia 2015; 21: 351–7.
37. Bullinger M, Globe D, Wasserman J et al. Challenges of patient-reported outcome assessment in hemophilia care–a state of the art review. Value Health 2009; 12: 808–20.
38. Santagostino E, Lentz SR, Busk AK et al. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia 2014; 20: 527–34.
39. Hanmer J, Cherepanov D, Palta M et al. Health condition impacts in a nationally representative cross-sectional survey vary substantially by preference-based health index. Med Decis Making 2016; 36: 264–74.
40. Groen WG, van der Net J, Helders PJ et al. Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List (pedhal). Haemophilia 2010; 16: 281–9.
41. World Federation of Hemophilia. Compendium of assessment tools. World Federation of Hemophilia website. Available at http://www.wfh.org/en/page.aspx?pid=882. Accessed November 25, 2015.
42. Padankatti SM, Macaden AS, Cherian SM et al. A patient-prioritized ability assessment in haemophilia: the Canadian Occupational Performance Measure. Haemophilia 2011; 17: 605–11.
43. Poonnoose PM, Manigandan C, Thomas R et al. Functional independence score in haemophilia: a new performance-based instrument to measure disability. Haemophilia 2005; 11: 598–602.
44. Poonnoose PM, Thomas R, Keshava SN et al. Psychometric analysis of the Functional Independence Score in Haemophilia (FISH). Haemophilia 2007; 13: 620–6.
45. US National Institutes of Health. PROMIS. NIH Website. http://www.nihpromis.org/. Available at http://www.nihpromis.org/default#1. Accessed November 18, 2015.
46. Dampier C, Jaeger B, Gross HE et al. Responsiveness of PROMIS((R)) pediatric measures to hospitalizations for sickle pain and subsequent recovery. Pediatr Blood Cancer 2016; 63: 1038–45.
47. Howell CR, Thompson LA, Gross HE et al. Responsiveness to change in PROMIS((R)) measures among children with asthma: a report from the PROMIS((R)) pediatric asthma study. Value Health 2016; 19: 192–201.
48. Hays RD, Spritzer KL, Fries JF et al. Responsiveness and minimally important difference for the patient-reported outcomes measurement information system (PROMIS) 20-item physical functioning short form in a prospective observational study of rheumatoid arthritis. Ann Rheum Dis 2015; 74: 104–7.
49. Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J 1968; 4: 443–53.
50. Bovendeert TJ, Botell RE, Wade DT. Writing SMART rehabilitation goals and achieving goal attainment scaling: a practical guide. Clin Rehabil 2009; 23: 352–61.
51. Rockwood K, Fay S, Song X et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ 2006; 174: 1099–105.
52. Turner-Stokes L. Goal attainment scaling and its relationship with standardized outcome measures: a commentary. J Rehabil Med 2011; 43: 70–2.
53. Ertzgaard P, Ward AB, Wissel J et al. Practical considerations for goal attainment scaling during rehabilitation following acquired brain injury. J Rehabil Med 2011; 43: 8–14.
54. Turner-Stokes L, Williams H. Goal attainment scaling: a direct comparison of alternative rating methods. Clin Rehabil 2010; 24: 66–73.
55. Neufeld EJ, Munn J, Honig D, Denne M, Richardson S, Rockwoode K. Development of a novel patient-centered outcome measure in hemophilia using goal attainment scaling. Presented at National Hemophilia Foundation's 67th Annual Meeting 2015 (NHF 2015) August 13–15, 2015. Grapevine, TX, USA.
56. Yip AM, Gorman MC, Stadnyk K et al. A standardized menu for goal attainment scaling in the care of frail elders. Gerontologist 1998; 38: 735–42.